Monte Rosa Therapeutics Reports $54.37M Revenue and $0.03 EPS
A $50 million Novartis milestone for MRT-6160 drove year-over-year growth in collaboration revenue. The company swung to net income from a year-earlier loss, with higher interest income contributing and higher research and development expenses partly offsetting the gains.
Monte Rosa Therapeutics’ collaboration revenue rose year over year as a $50 million milestone from Novartis for MRT-6160 drove the increase. The company swung to net income from a year-earlier loss, reflecting higher collaboration revenue and interest income, partly offset by higher research and de…